Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Santen Nabs Distribution Rights to Beovu, Lucentis in South Korea
October 21, 2025
- Chugai, Rani Therapeutics Strike Deal on Oral Antibody Drug
October 21, 2025
- Chugai to File Tecentriq for Adjuvant Bladder Cancer Use in 2026 after Positive Data
October 21, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- Meiji Completes New Facilities to Restart Domestic Production of 6-APA
October 20, 2025
- Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
October 20, 2025
- iPark, KoreaBIO Ink MOU to Fuel Japan-Korea Cooperation in Life Sciences
October 20, 2025
- Novo, JAST Join Hands to Raise Awareness of Obesity
October 20, 2025
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- Lilly Japan Teams Up with 23 Medical Societies to Strengthen Obesity Care
October 17, 2025
- Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
- Organon Bids Farewell to 1990s Blockbusters Lipovas and Renivace in Japan
October 16, 2025
- ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
October 15, 2025
- Sanofi, NIID Sign MOU on Infectious Disease Collaboration
October 15, 2025
- Astellas’ Vyloy Combo Fails to Improve Survival in PII Pancreatic Cancer Study
October 15, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- Novo, Sumitomo Extend Co-Promotion Partnership to Wegovy
October 15, 2025
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Chugai to Develop Roche’s GLP-1/GIP Agent CT-388 in Japan
October 14, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…